Comment
doi: 10.1007/s11912-005-0074-1.
Docetaxel-based chemotherapy trials in androgen-independent prostate cancer: first demonstration of a survival benefit
Affiliations
- PMID: 15847711
- DOI: 10.1007/s11912-005-0074-1
Item in Clipboard
Comment
Docetaxel-based chemotherapy trials in androgen-independent prostate cancer: first demonstration of a survival benefit
Curr Oncol Rep.
2005 May.
No abstract available
Comment on
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.N Engl J Med. 2004 Oct 7;351(15):1502-12. doi: 10.1056/NEJMoa040720. N Engl J Med. 2004. PMID: 15470213 Clinical Trial.
-
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.N Engl J Med. 2004 Oct 7;351(15):1513-20. doi: 10.1056/NEJMoa041318. N Engl J Med. 2004. PMID: 15470214 Clinical Trial.
Similar articles
-
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.Lancet Oncol. 2015 Jul;16(7):787-94. doi: 10.1016/S1470-2045(15)00011-X. Epub 2015 May 28. Lancet Oncol. 2015. PMID: 26028518 Clinical Trial.
-
A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.J Urol. 2007 Jun;177(6):2141-5; discussion 2145. doi: 10.1016/j.juro.2007.01.148. J Urol. 2007. PMID: 17509302 Clinical Trial.
-
Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.Eur Urol. 2016 Apr;69(4):563-573. doi: 10.1016/j.eururo.2015.09.013. Epub 2015 Sep 28. Eur Urol. 2016. PMID: 26422676 Review.
-
Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.J Urol. 2003 May;169(5):1729-34. doi: 10.1097/01.ju.0000062500.75703.2c. J Urol. 2003. PMID: 12686819
-
Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.Oncologist. 2005;10 Suppl 3:30-9. doi: 10.1634/theoncologist.10-90003-30. Oncologist. 2005. PMID: 16368869 Review.
Cited by
-
[How should hormone therapy for castration-resistant prostate cancer be continued?].Urologe A. 2012 Jan;51(1):15-9. doi: 10.1007/s00120-011-2738-9. Urologe A. 2012. PMID: 22258371 German.
-
Metastatic prostate cancer in 2015: The new and the old that is new again.Nat Rev Clin Oncol. 2016 Feb;13(2):73-4. doi: 10.1038/nrclinonc.2015.226. Epub 2015 Dec 31. Nat Rev Clin Oncol. 2016. PMID: 26718107 No abstract available.
-
Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization.Prostate. 2009 May 1;69(6):571-84. doi: 10.1002/pros.20906. Prostate. 2009. PMID: 19143030 Free PMC article.